Snake Bite - Copperhead - Water Moccasin - Rattlesnake - Cottonmouth - Coral Snake - Trauma CME EMP-September-Fullsize
EMPOWERING PHYSICIANS WITH EVIDENCE-BASED CONTENT
 

Home > Browse Topics

Emergency Department Management of North American Snake Envenomations (Trauma CME)

Snake Bite - Copperhead - Water Moccasin - Rattlesnake - Cottonmouth - Coral Snake - Trauma CME - Cover

Emergency Department Management of North American Snake Envenomations - Trauma CME

Facebook - Snake Bite - Copperhead - Water Moccasin - Rattlesnake - Cottonmouth - Coral Snake - Trauma CME Twitter - Snake Bite - Copperhead - Water Moccasin - Rattlesnake - Cottonmouth - Coral Snake - Trauma CME Linkedin - Snake Bite - Copperhead - Water Moccasin - Rattlesnake - Cottonmouth - Coral Snake - Trauma CME

  About This Issue

Venomous native North American snake families include the pit vipers (copperheads, water moccasins/cottonmouths, and rattlesnakes) and coral snakes. Pit viper venom is coagulopathic, and coral snake venom is neurotoxic – so what are the differences in ED management between the 2 types of envenomations? This issue reviews the best evidence behind some of the conflicting recommendations, local practices, and “folklore” surrounding snakebites:

•  Ice, pressure immobilization, incision and suction: are they still recommended?
•  How can you tell whether - and how much - venom was injected?
•  Why you must mark and time edema and erythema from a snakebite
•  What can antivenom do - and not do?
•  What are the antivenom options for coral snake bites?
•  When is airway compromise a concern, and will antivenom reverse it?
•  Is there a greater risk for anaphylaxis from the snakebite or the antivenom?
•  What is the likelihood of bleeding days or weeks after a snakebite?
•  What are the different observation time recommendations, based on type of snake and bite severity?

  Issue Information

Author: Sophia Sheikh, MD; Patrick Leffers, PharmD

Peer Reviewers: Daniel J. Sessions, MD; Andy Jagoda, MD, FACEP

Publication Date: September 1, 2018

CME Expiration Date: September 1, 2021

CME Credits: 4 AMA PRA Category 1 CreditsTM, 4 ACEP Category I Credits, 4 AAFP Prescribed Credits, 4 AOA Category 2A or 2B Credits.  Included as part of the 4 credits, this CME activity is eligible for 4 Trauma CME credits.

PubMed ID: 30130010

  Issue Features
  Table of Contents
  1. Abstract
  2. Case Presentations
  3. Introduction
  4. Critical Appraisal of the Literature
  5. Epidemiology and Pathophysiology
    1. Snakebite Severity
    2. Crotalinae Family: The Pit Vipers
    3. Elapidae Family: The Coral Snakes
  6. Differential Diagnosis
  7. Prehospital Care
    1. Pressure Immobilization
  8. Emergency Department Evaluation
    1. Initial Assessment and Stabilization
    2. History
    3. Physical Examination
      1. Cardiovascular Effects
      2. Respiratory Effects
      3. Neurologic Effects
      4. Hematologic Effects
      5. Dermal Effects
      6. Musculoskeletal Effects
      7. Rare Reported Effects
  9. Diagnostic Studies
    1. General Recommendations
    2. Coagulation Studies
    3. Imaging
    4. Monitoring/Observation
  10. Treatment
    1. Grading of Envenomation Severity to Guide Treatment With Antivenom
    2. Antivenom Treatment of Pit Viper Envenomation
      1. FabAV (CroFab®)
        • Dosing of FabAV
        • Contraindications for FabAV
        • Use of FabAV for Copperhead Envenomation
        • Use of FabAV in Compartment Syndrome
        • Use of FabAV in Coagulopathy
    3. Antivenom Treatment of Coral Snake Envenomation
      1. Dosage of North American Coral Snake Antivenin (Equine)
      2. Experimental Coral Snake Antivenoms and Treatments
    4. Treatment of Non–Native Snake Envenomation
  11. Special Populations
    1. Pregnant Patients
    2. Pediatric Patients
    3. Anticoagulated Patients
  12. Controversies and Cutting Edge
    1. Controversies
    2. Cutting Edge
      1. F(ab’)2 (Anavip®)
  13. Disposition
    1. Observation
    2. Admission
    3. Follow-Up
  14. Summary
  15. Risk Management Pitfalls for Managing Patients With Snakebites in the Emergency Department
  16. Time- and Cost-Effective Strategies
  17. Case Conclusions
  18. Clinical Pathways
    1. Clinical Pathway for Management of Patients With North American Pit Viper Bite
    2. Clinical Pathway for Management of Patients With North American Coral Snake Bite
  19. Tables and Figures
    1. Table 1. Number of Reported Snake Exposures and Fatalities in the United States, 2006-2015
    2. Table 2. Snake Venom Components and Their Clinical Effects
    3. Table 3. Prehospital Management of North American Pit Viper Envenomations
    4. Table 4. Venom-Induced Clinical Effects and Their Treatment
    5. Figure 1. Comparison of Pit Viper and Nonvenomous Snake Characteristics
    6. Figure 2. Crotalinae (Pit Viper) Distribution in North America
    7. Figure 3. Elapidae (Coral Snake) Distribution in North America
  20. References

 

Abstract

There are approximately 10,000 emergency department visits in the United States for snakebites every year, and one-third of those involve venomous species. Venomous North American indigenous snakes include species from the Crotalinae (pit vipers) and Elapidae (coral snakes) subfamilies. Treatment relies on supportive care, plus antivenom for select cases. While certain principles of management are widely accepted, controversies exist with regard to prehospital use of pressure immobilization, antivenom use, coagulation testing after copperhead envenomation, and fasciotomy. An evidence-based approach to management of North American venomous snakes will be discussed, along with a review of the current controversies.

 

Case Presentations

A 4-year-old boy is brought to your ED by his distraught parents. An hour ago, he was in the backyard by the pool, playing with what they thought was a toy. He started screaming, and when the mother moved closer, she saw a foot-long black, yellow, and red snake in his hand. She frantically pulled it off him and threw it into the bushes. She reports that she had to pull quite hard before it would release. The child has several small marks on the palm of his left hand. There is minimal redness, and no swelling is apparent. The dad took a picture of the snake with his phone and you can tell quickly that it was a coral snake. The child is asymptomatic currently, but the nearest pediatric ICU is over an hour away. You wonder: should you transfer this patient to the ICU or can you observe him in the ED—and should you start antivenom?

A 26-year-old man arrives to the ED via private vehicle with his arm in a makeshift sling. He reports that his pet rattlesnake bit him on his right index finger about 45 minutes ago. His hand and wrist are swollen. He reports that he has no past medical history besides his 3 previous visits for snakebites. He reports having a “reaction” to the snakebite antidote during his last visit. You wonder whether the patient is immune . . . or should you give antivenom again?

A 51-year-old man with a history of a rattlesnake bite approximately 4 days ago presents from his primary care physician's office for abnormal lab test results. He reports easy bruising and some bleeding when he brushes his teeth, but is otherwise asymptomatic. You wonder how you should manage this patient.

 

Introduction

According to the American Association of Poison Control Centers (AAPCC) 2006-2015 annual reports, there were 65,695 reported exposures and 31 deaths from snakes in the United States in that time period.1 There are 2 subfamilies of venomous snakes that are native to the United States: (1) the Crotalinae (pit vipers, subfamily of family Viperidae), which includes rattlesnakes, copperheads, and water moccasins (also called cottonmouths), and (2) the subfamily Elapidae (subfamily of family Colubridae) of which only the coral snake is native to the United States. Bites from snakes from these native subfamilies can produce significant morbidity and, rarely, death, so prompt clinical evaluation and management is essential. In addition, exotic snakes are popular as pets, and bites from these snakes may cause rapid death, depending on the species, so expertise is required to manage them expeditiously.

Patients with snake envenomations generally access healthcare either through the emergency department (ED) or through first-aid providers who generally turn to the emergency clinician for direction. Management of envenomations is considered a core competency of emergency clinicians, and along with Poison Control Centers, they often serve as community resources for snakebite emergencies. Not all envenomations require antivenom; however, delayed administration may lead to significant morbidity and even death, in some cases. This issue of Emergency Medicine Practice provides a comprehensive update on the principles of clinical evaluation of envenomations from pit vipers and coral snakes native to the United States as well as current management recommendations and controversies. Resources are also provided to assist in the management of envenomation from exotic species.

 

Critical Appraisal of the Literature

A literature search was performed on PubMed using the search terms snake bites, snake envenomation, Agkistrodon, cottonmouth, copperhead, rattlesnake, Crotalinae, Elapidae, Colubridae, water moccasin, coral snake, and pit viper. A total of 120 relevant articles from 2006 to 2017 were reviewed.

A search of literature published from 2006 to 2017 using key terms snake bite or snake envenomation of the Cochrane Database of Systematic Reviews, Evidence Based Medicine Reviews: Best Evidence (ACP), Database of Abstracts of Reviews of Effectiveness (DARE), and Evidence-Based Medicine Reviews Multifile (EBMZ) identified 11 articles. Of these, 3 were not relevant to indigenous North American snakes, 3 were randomized controlled trials, 1 was a poststudy subanalysis, and 2 were reviews (Cochrane and DARE).

As is the case with most of the toxicology literature, evidence on the management of snake envenomations from high-quality prospective randomized controlled trials is limited. The few published studies in the past 10 years are mostly from other countries where the snake species, the level of supportive care, and antivenom availability and effectiveness are different from that in North America. The literature is comprised primarily of case reports/series, retrospective chart reviews, animal model studies, expert consensus panels, and review articles.

The current relevant literature is comprised of case reports/series describing novel or known but not well-characterized clinical effects after a snake envenomation; observational studies using data from hospital charts, Internet search, Poison Control Centers, and national databases; animal model studies; in vitro venom and antivenom studies; conclusions from expert consensus panels; a position statement; and 3 randomized controlled trials. Many of the retrospective observation studies utilized Poison Control Center data (Texas Poison Control Center Network, Florida Poison Information Center Network, AAPCC database, and the American College of Medical Toxicology ToxIC North American Snakebite Registry). Poison Control Centers collect self-reported, unverified information provided by the public or healthcare workers on potential or actual exposures, but they may not be true envenomations and may not reflect the true incidence of snakebites. Furthermore, reported clinical effects and outcomes may be incomplete or inaccurate. For example, according to a compilation of data reported to United States Poison Control Centers, there were no deaths from coral snakes from 2006 to 2015; however, a confirmed death after a coral snake envenomation was published in 2009 (the first and only confirmed death in the literature).2 The ToxIC Registry contains prospectively collected verified clinical information, and it also relies on voluntary reporting.

Most of the management recommendations discussed in this article are based on expert opinion supported by low- to moderate-quality evidence. Expert consensus panel recommendations for the surgical management of snake envenomation were published in 2013.3 Clinical questions were structured in the “Patient, Intervention, Comparison, Outcome” format, and recommendations were developed using Grading of Recommendations, Assessment, Development, and Evaluation. A unified treatment algorithm for the management of Crotalinae envenomations was published in 2011.4 Experts utilized a modified Delphi methodology to develop evidence-informed recommendations. Standard evidence-level scales were not used, as only 1 randomized clinical trial involving the treatment of Crotalinae envenomation with antivenom had been published at the time.5 Since then, a randomized clinical trial comparing Crotalidae Polyvalent Immune Fab (Ovine) (FabAV, CroFab®) to F(ab’)2 immunoglobulin derivatives was published in 2015.6 Additionally, a post hoc analysis of data from this trial comparing copperhead coagulation parameters was also published.7 A position statement from leading national and international clinical toxicology associations regarding use of pressure immobilization after a North American Crotalinae snake envenomation was published in 2011.8

 

Risk-Management-Pitfalls-for-Managing-Patients-With-Snakebites-in-the-Emergency-Department

1. “The patient had some minor abrasions, but no visible fang marks, pain, or swelling at the bite site, so I discharged him.”

Patients can develop a coagulopathy and covert bleeding from pit viper bites without having visible tissue damage. The patient should be observed for a minimum of 8 hours, and coagulation studies repeated before discharge home. Coral snake bites may not produce any visible signs on examination. If a coral snake is the suspected culprit, the patient should be monitored for 24 hours to ensure delayed symptoms do not develop.

3. “I thought that I could wait until signs of respiratory distress developed, because the antivenom would quickly reverse the paralysis.”

Administration of antivenom does not reverse symptoms; it merely halts progression of symptoms. Patients with coral snake bites should be treated with antivenom at the first signs of neurological impairment.

7. “The patient had urticaria and wheezing that developed soon after I started administering antivenom, so I stopped the infusion. The patient continued to worsen, even though I stopped it.”

Allergic reaction to antivenom is a serious adverse effect; however, patients can also develop anaphylaxis and other allergic symptoms to snake venom. For each case, consider this possibility and weigh the risks of not treating a snakebite. Consultation with a regional Poison Control Center is recommended.

 

Tables and Figures

Table 1. Number of Reported Snake Exposures and Fatalities in the United States, 2006-2015.

 

 

 

References

Evidence-based medicine requires a critical appraisal of the literature based upon study methodology and number of subjects. Not all references are equally robust. The findings of a large, prospective, randomized, and blinded trial should carry more weight than a case report.

To help the reader judge the strength of each reference, pertinent information about the study, such as the type of study and the number of patients in the study is included in bold type following the references, where available. In addition, the most informative references cited in this paper, as determined by the author, are highlighted.

  1. Mowry JB, Spyker DA, Brooks DE, et al. 2015 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 33rd annual report. Clin Toxicol (Phila). 2016;54(10):924-1109. (Retrospective review; 339 patients)
  2. Norris RL, Pfalzgraf RR, Laing G. Death following coral snake bite in the United States--first documented case (with ELISA confirmation of envenomation) in over 40 years. Toxicon. 2009;53(6):693-697. (Case report)
  3. Toschlog EA, Bauer CR, Hall EL, et al. Surgical considerations in the management of pit viper snake envenomation. J Am Coll Surg. 2013;217(4):726-735. (Consensus panel)
  4. Lavonas EJ, Ruha AM, Banner W, et al. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med. 2011;11:2-227X-11-2. (Consensus panel)
  5. Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of Crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med. 2001;161(16):2030-2036. (Randomized controlled trial; 31 patients)
  6. Bush SP, Ruha AM, Seifert SA, et al. Comparison of F(ab’)2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial. Clin Toxicol (Phila). 2015;53(1):37-45. (Randomized controlled trial; 121 patients)
  7. Gerardo CJ, Vissoci JR, Brown MW, et al. Coagulation parameters in copperhead compared to other Crotalinae envenomation: secondary analysis of the F(ab’)2 versus Fab antivenom trial. Clin Toxicol (Phila). 2017;55(2):109-114. (Randomized controlled trial; 121 patients)
  8. American College of Medical Toxicology, American Academy of Clinical Toxicology, American Association of Poison Control Centers, European Association of Poison Control Centres and Clinical Toxicologists, International Society on Toxinology, Asia Pacific Association of Medical Toxicology. Pressure immobilization after North American Crotalinae snake envenomation. Clin Toxicol (Phila). 2011;49(10):881-882. (Position statement)
  9. Seifert SA, Boyer LV, Benson BE, et al. AAPCC database characterization of native U.S. venomous snake exposures, 2001-2005. Clin Toxicol (Phila). 2009;47(4):327-335. (Retrospective; 23,676 patients)
  10. Wood A, Schauben J, Thundiyil J, et al. Review of eastern coral snake (Micrurus fulvius fulvius) exposures managed by the Florida Poison Information Center Network: 1998-2010. Clin Toxicol (Phila). 2013;51(8):783-788. (Retrospective; 387 patients)
  11. Morgan DL, Borys DJ, Stanford R, et al. Texas coral snake (Micrurus tener) bites. South Med J. 2007;100(2):152-156. (Retrospective; 82 patients)
  12. Spano S, Macias F, Snowden B, et al. Snakebite survivors club: retrospective review of rattlesnake bites in Central California. Toxicon. 2013;69:38-41. (Retrospective; 46 patients)
  13. Wasko DK, Bullard SG. An analysis of media-reported venomous snakebites in the United States, 2011-2013. Wilderness Environ Med. 2016;27(2):219-226. (Retrospective; 332 patients)
  14. Ruha et al. Epidemiology, Clinical Course, and Management of Snakebites in the North American Snake Bite Registry. J Med Toxicol. 2017;13(4):309-320. (Retrospective; 450 patients)
  15. O’Neil ME, Mack KA, Gilchrist J, et al. Snakebite injuries treated in United States emergency departments, 2001-2004. Wilderness Environ Med. 2007;18(4):281-287. (Retrospective; 9873 patients)
  16. Abbey JM, Jaffar NA, Abugrara HL, et al. Epidemiological characteristics, hospital course and outcome of snakebite victims in West Texas. Hosp Pract (1995). 2015;43(4):217-220. (Retrospective; 90 patients)
  17. Hayes WK, Mackessy SP. Sensationalistic journalism and tales of snakebite: are rattlesnakes rapidly evolving more toxic venom? Wilderness Environ Med. 2010;21(1):35-45. (Concept)
  18. Herbert SS, Hayes WK. Denim clothing reduces venom expenditure by rattlesnakes striking defensively at model human limbs. Ann Emerg Med. 2009;54(6):830-836. (Model study)
  19. Janes DN Jr, Bush SP, Kolluru GR. Large snake size suggests increased snakebite severity in patients bitten by rattlesnakes in Southern California. Wilderness Environ Med. 2010;21(2):120-126. (Retrospective; 145 patients)
  20. Naik BS. “Dry bite” in venomous snakes: a review. Toxicon. 2017;133:63-67. (Review)
  21. Massey DJ, Calvete JJ, Sanchez EE, et al. Venom variability and envenoming severity outcomes of the Crotalus scutulatus scutulatus (Mojave rattlesnake) from Southern Arizona. J Proteomics. 2012;75(9):2576-2587. (Laboratory testing)
  22. Rokyta DR, Wray KP, Margres MJ. The genesis of an exceptionally lethal venom in the timber rattlesnake (Crotalus horridus) revealed through comparative venom-gland transcriptomics. BMC Genomics. 2013;14:394-2164-14-394. (Laboratory testing)
  23. Jansen PW, Perkin RM, Van Stralen D. Mojave rattlesnake envenomation: prolonged neurotoxicity and rhabdomyolysis. Ann Emerg Med. 1992;21(3):322-325. (Case report)
  24. Richardson WH, Goto CS, Gutglass DJ, et al. Rattlesnake envenomation with neurotoxicity refractory to treatment with crotaline Fab antivenom. Clin Toxicol (Phila). 2007;45(5):472-475. (Case report)
  25. Madey JJ, Price AB, Dobson JV, et al. Facial diplegia, pharyngeal paralysis, and ophthalmoplegia after a timber rattlesnake envenomation. Pediatr Emerg Care. 2013;29(11):1213-1216. (Case report)
  26. Fazelat J, Teperman SH, Touger M. Recurrent hemorrhage after western diamondback rattlesnake envenomation treated with Crotalidae polyvalent immune Fab (ovine). Clin Toxicol (Phila). 2008;46(9):823-826. (Case report)
  27. Bosak AR, Ruha AM, Graeme KA. A case of neurotoxicity following envenomation by the sidewinder rattlesnake, Crotalus cerastes. J Med Toxicol. 2014;10(2):229-231. (Case report)
  28. Spano SJ, Vohra R, Macias F. Long-term complications of rattlesnake bites: a telephone survey from Central California. Wilderness Environ Med. 2014;25(2):210-213. (Survey; 46 patients)
  29. Spiller HA, Bosse GM, Ryan ML. Use of antivenom for snakebites reported to United States poison centers. Am J Emerg Med. 2010;28(7):780-785. (Retrospective; 37,760 patients)
  30. Zad O, Cooper H, Crocker P, et al. Shock, respiratory failure, and coagulopathy after an intravenous copperhead envenomation. Am J Emerg Med. 2009;27(3):377.e1-377. (Case report)
  31. Whitley RE. Conservative treatment of copperhead snakebites without antivenin. J Trauma. 1996;41(2):219-221. (Retrospective; 55 patients)
  32. Lavonas EJ, Gerardo CJ, Copperhead Snakebite Recovery Outcome Group. Prospective study of recovery from copperhead snake envenomation: an observational study. BMC Emerg Med. 2015;15:9-015-0033-6. (Prospective; 20 patients)
  33. Roth B, Sharma K, Onisko N, et al. Prospective evaluation of pain, swelling, and disability from copperhead envenomation. Clin Toxicol (Phila). 2016;54(3):271-276. (Prospective; 87 patients)
  34. Savage JM, Slowinski JB .The colouration of the venomous coral snakes (family Elapidae) and their mimics (families Aniliidae and Colubridae). Biological Journal of the Linnean Society. 1992;45(3):235-254. (Review)
  35. Meggs WJ, Courtney C, O’Rourke D, et al. Pilot studies of pressure-immobilization bandages for rattlesnake envenomations. Clin Toxicol (Phila). 2010;48(1):61-63. (Animal model)
  36. Seifert S, White J, Currie BJ. Pressure bandaging for North American snake bite? No! Clin Toxicol (Phila). 2011;49(10):883-885. (Concept)
  37. Markenson D, Ferguson JD, Chameides L, et al. Part 17: first aid: 2010 American Heart Association and American Red Cross guidelines for first aid. Circulation. 2010;122(18 Suppl 3):S934-46. (Guidelines)
  38. German BT, Hack JB, Brewer K, et al. Pressure-immobilization bandages delay toxicity in a porcine model of eastern coral snake (Micrurus fulvius fulvius) envenomation. Ann Emerg Med. 2005;45(6):603-608. (Animal model)
  39. Smyrnioudis ME, O’Rourke DP, Rosenbaum MD, et al. Long-term efficacy of pressure immobilization bandages in a porcine model of coral snake envenomation. Am J Emerg Med. 2014;32(9):1024-1026. (Animal model)
  40. Norris RL, Ngo J, Nolan K, et al. Physicians and lay people are unable to apply pressure immobilization properly in a simulated snakebite scenario. Wilderness Environ Med. 2005;16(1):16-21. (Simulation)
  41. Simpson ID, Tanwar PD, Andrade C, et al. The Ebbinghaus retention curve: training does not increase the ability to apply pressure immobilisation in simulated snake bite--implications for snake bite first aid in the developing world. Trans R Soc Trop Med Hyg. 2008;102(5):451-459. (Simulation)
  42. Wilbeck J, Gresham C. North American snake and scorpion envenomations. Crit Care Nurs Clin North Am. 2013;25(2):173-190. (Review)
  43. Brooks DE, Graeme KA. Airway compromise after first rattlesnake envenomation. Wilderness Environ Med. 2004;15(3):188-193. (Case report)
  44. Prescott RA, Potter PC. Hypersensitivity to airborne spitting cobra snake venom. Ann Allergy Asthma Immunol. 2005;94(5):600-603. (Case report)
  45. Norris RL, Wilkerson JA, Feldman J. Syncope, massive aspiration, and sudden death following rattlesnake bite. Wilderness Environ Med. 2007;18(3):206-208. (Case report)
  46. Kanaan NC, Ray J, Stewart M, et al. Wilderness Medical Society practice guidelines for the treatment of pitviper envenomations in the United States and Canada. Wilderness Environ Med. 2015;26(4):472-487. (Review)
  47. Garfin SR, Castilonia RR, Mubarak SJ, et al. Rattlesnake bites and surgical decompression: results using a laboratory model. Toxicon. 1984;22(2):177-182. (Animal model)
  48. Cumpston KL. Is there a role for fasciotomy in Crotalinae envenomations in North America? Clin Toxicol (Phila). 2011;49(5):351-365. (Review)
  49. Quan D. North American poisonous bites and stings. Crit Care Clin. 2012;28(4):633-659. (Review)
  50. Morgan DL, Borys DJ. Onset of systemic effects from bites of the Texas coral snake. Ann Emerg Med. 2007;50(3):S27. (Case series; 123 patients)
  51. Gold BS, Dart RC, Barish RA. Bites of venomous snakes. N Engl J Med 2002;347(5);347-356. (Review)
  52. Vohra R, Cantrell FL, Williams SR. Fasciculations after rattlesnake envenomations: a retrospective statewide Poison Control System study. Clin Toxicol (Phila). 2008;46(2):117-121. (Retrospective; 47 patients)
  53. Levine M, Ruha AM, Padilla-Jones A, et al. Bleeding following rattlesnake envenomation in patients with preenvenomation use of antiplatelet or anticoagulant medications. Acad Emerg Med. 2014;21(3):301-307. (Retrospective; 319 patients)
  54. Bucaretchi F, Hyslop S, Vieira RJ, et al. Bites by coral snakes (Micrurus spp.) in Campinas, state of Sao Paulo, Southeastern Brazil. Rev Inst Med Trop Sao Paulo. 2006;48(3):141-145. (Retrospective; 11 patients)
  55. Ramirez RN, Umberhandt R, Oishi SN, et al. Digital chondrolysis and epiphysiolysis associated with snakebite: a report of 2 cases. J Pediatr Orthop. 2015;35(6):e60-e64. (Case series; 2 patients)
  56. Khimani A, McNierney A, Surani S, et al. Snake envenomation causing distant tracheal myonecrosis. Case Rep Pulmonol. 2013;2013:364195. (Case report)
  57. Bonasso P, Lucke-Wold B, Jacob G. Osteonecrosis of interphalangeal joint of thumb two months after rattlesnake bite. Hand Surg. 2015;20(2):330-332. (Case report)
  58. Bush SP, Mooy GG, Phan TH. Catastrophic acute ischemic stroke after Crotalidae polyvalent immune Fab (ovine)-treated rattlesnake envenomation. Wilderness Environ Med. 2014;25(2):198-203. (Case report)
  59. Vale TC, Leite AF, Hora PR, et al. Bilateral posterior circulation stroke secondary to a crotalid envenomation: case report. Rev Soc Bras Med Trop. 2013;46(2):255-256. (Case report)
  60. Lee L, Yao J. Stenosing flexor tenosynovitis following a rattlesnake bite. Orthopedics. 2010;33(7):515-20100526-20. (Case report)
  61. Bhagat R, Sharma K, Sarode R, et al. Delayed massive pulmonary thromboembolic phenomenon following envenomation by Mojave rattlesnake (Crotalus scutulatus). Thromb Haemost. 2010;104(1):186-188. (Case report)
  62. Gonzalez M, Sanchez R, Carrillo EH. Septic shock syndrome resulting from snakebite. J Trauma. 2010;68(4):1015. (Case report)
  63. Moriarity RS, Dryer S, Replogle W, et al. The role for coagulation markers in mild snakebite envenomations. West J Emerg Med. 2012;13(1):68-74. (Retrospective; 131 patients)
  64. Ali AJ, Horwitz DA, Mullins ME. Lack of coagulopathy after copperhead snakebites. Ann Emerg Med. 2015;65(4):404-409. (Retrospective; 106 patients)
  65. Vohra R, Rangan C, Bengiamin R. Sonographic signs of snakebite. Clin Toxicol (Phila). 2014;52(9):948-951. (Prospective; 13 patients)
  66. Dart RC, Hurlbut KM, Garcia R, et al. Validation of a severity score for the assessment of crotalid snakebite. Ann Emerg Med. 1996;27(3):321-326. (Retrospective; 108 patients)
  67. Russell FE. Snake Venom Poisoning. Scholium International, Great Neck, New York;1983. (Book)
  68. Van Mierop LH. Poisonous snakebite: a review. 2. Symptomology and treatment. J Fla Med Assoc. 1976;63(3):201-210. (Review)
  69. Nishioka SA. Limitations of the snakebite severity score. Ann Emerg Med. 1996;28(3):371-372. (Letter to editor)
  70. King AM, Crim WS, Menke NB, et al. Pygmy rattlesnake envenomation treated with Crotalidae polyvalent immune Fab antivenom. Toxicon. 2012;60(7):1287-1289. (Case report)
  71. Yin S, Kokko J, Lavonas E, et al. Factors associated with difficulty achieving initial control with Crotalidae polyvalent immune Fab antivenom in snakebite patients. Acad Emerg Med. 2011;18(1):46-52. (Retrospective; 247 patients)
  72. Schaeffer TH, Khatri V, Reifler LM, et al J. Incidence of immediate hypersensitivity reaction and serum sickness following administration of Crotalidae polyvalent immune Fab antivenom: a meta-analysis. Acad Emerg Med. 2012;19(2):121-131. (Review)
  73. Cannon R, Ruha AM, Kashani J. Acute hypersensitivity reactions associated with administration of Crotalidae polyvalent immune Fab antivenom. Ann Emerg Med. 2008;51(4):407-411. (Retrospective; 93 patients)
  74. US Food and Drug Administration. Package Insert - CROFAB - FDA. Available at: www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/Approved
    Products/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm117573.pdf
    . Accessed August 10, 2018. (Product insert)
  75. Walker JP, Morrison RL. Current management of copperhead snakebite. J Am Coll Surg. 2011;212(4):470-474. (Retrospective; 142 patients)
  76. Gerardo CJ, Quackenbush E, Lewis B, et al. The efficacy of Crotalidae polyvalent immune Fab (ovine) antivenom versus placebo plus optional rescue therapy on recovery from copperhead snake envenomation: a randomized, double-blind, placebo-controlled, clinical trial. Ann Emerg Med. 2017;70(2):233-244.e3. (Randomized controlled trial; 74 patients)
  77. Tanen DA, Danish DC, Grice GA, et al. Fasciotomy worsens the amount of myonecrosis in a porcine model of crotaline envenomation. Ann Emerg Med. 2004;44(2):99-104. (Animal model)
  78. Mazer-Amirshahi M, Boutsikaris A, Clancy C. Elevated compartment pressures from copperhead envenomation successfully treated with antivenin. J Emerg Med. 2014;46(1):34-37. (Case report)
  79. Tanen DA, Danish DC, Clark RF. Crotalidae polyvalent immune Fab antivenom limits the decrease in perfusion pressure of the anterior leg compartment in a porcine crotaline envenomation model. Ann Emerg Med. 2003;41(3):384-390. (Animal model)
  80. Ruha AM, Curry SC. Recombinant factor VIIa for treatment of gastrointestinal hemorrhage following rattlesnake envenomation. Wilderness Environ Med. 2009;20(2):156-160. (Case report)
  81. Kitchens C, Eskin T. Fatality in a case of envenomation by Crotalus adamanteus initially successfully treated with polyvalent ovine antivenom followed by recurrence of defibrinogenation syndrome. J Med Toxicol. 2008;4(3):180-183. (Case report)
  82. Seifert SA, I Kirschner R, Martin N. Recurrent, persistent, or late, new-onset hematologic abnormalities in crotaline snakebite. Clin Toxicol (Phila). 2011;49(4):324-329. (Retrospective; 60 patients)
  83. Lavonas EJ, Khatri V, Daugherty C, et al. Medically significant late bleeding after treated crotaline envenomation: a systematic review. Ann Emerg Med. 2014;63(1):71-78. (Review)
  84. Miller AD, Young MC, DeMott MC, et al. Recurrent coagulopathy and thrombocytopenia in children treated with Crotalidae polyvalent immune Fab: a case series. Pediatr Emerg Care. 2010;26(8):576-582. (Case series; 4 patients)
  85. Witham WR, McNeill C, Patel S. Rebound coagulopathy in patients with snakebite presenting with marked initial coagulopathy. Wilderness Environ Med. 2015;26(2):211-215. (Retrospective; 3 patients)
  86. Boyer LV, Seifert SA, Clark RF, et al. Recurrent and persistent coagulopathy following pit viper envenomation. Arch Intern Med. 1999;159(7):706-710. (Prospective; 38 patients)
  87. Boyer LV, Seifert SA, Cain JS. Recurrence phenomena after immunoglobulin therapy for snake envenomations: part 2. Guidelines for clinical management with crotaline Fab antivenom. Ann Emerg Med. 2001;37(2):196-201. (Guidelines)
  88. Seifert SA, Boyer LV. Recurrence phenomena after immunoglobulin therapy for snake envenomations: part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies. Ann Emerg Med. 2001;37(2):189-195. (Guidelines)
  89. Seifert SA, Cano DN. Late, new-onset thrombocytopenia in a rattlesnake envenomation treated with a Fab antivenom. Clin Toxicol (Phila). 2013;51(9):911-912. (Letter to editor)
  90. United States Food and Drug Administration. Expiration date extension for North American Coral Snake Antivenin (Micrurus fulvius) (equine origin) Lot L67530 through January 31, 2018. Available at: https://www.fda.gov/biologicsbloodvaccines/safetyavailability/ucm538841.htm. Accessed August 10, 2018. (Government statement)
  91. Walter FG, Stolz U, Shirazi F, et al. Temporal analyses of coral snakebite severity published in the American Association of Poison Control Centers’ Annual Reports from 1983 through 2007. Clin Toxicol. (Phila) 2010;48(1):72-78. (Retrospective study of AAPCC data)
  92. Seifert SA. Evaluation and management of coral snakebites. UpToDate. Accessed August 10, 2018. (Review)
  93. Sanchez EE, Lopez-Johnston JC, Rodriguez-Acosta A, et al. Neutralization of two North American coral snake venoms with United States and Mexican antivenoms. Toxicon. 2008;51(2):297-303. (Lab)
  94. U.S. National Library of Medicine, www.clinicaltrials.gov. Emergency treatment of coral snake envenomation with antivenom. Available at: https://clinicaltrials.gov/ct2/show/NCT01337245?term=coral+snake&rank=1. Accessed August 10, 2018. (Clinical trial record)
  95. Parker-Cote JL, O’Rourke DP, Brewer KL, et al. Efficacy of trypsin in treating coral snake envenomation in the porcine model. J Med Toxicol. 2015;11(4):430-432. (Animal model)
  96. Bucaretchi F, Capitani EM, Vieira RJ, et al. Coral snake bites (Micrurus spp.) in Brazil: a review of literature reports. Clin Toxicol (Phila). 2016;54(3):222-234. (Review)
  97. LaMonica GE, Seifert SA, Rayburn WF. Rattlesnake bites in pregnant women. J Reprod Med. 2010;55(11-12):520-522. (Retrospective; 11 patients)
  98. Seneviratne SL, de Silva CE, Fonseka MM, et al. Envenoming due to snake bite during pregnancy. Trans R Soc Trop Med Hyg. 2002;96(3):272-274. (Prospective; 39 patients)
  99. Brown SA, Seifert SA, Rayburn WF. Management of envenomations during pregnancy. Clin Toxicol (Phila). 2013;51(1):3-15. (Review)
  100. United States Food and Drug Administration. Thimerosal and vaccines. Available at: https://www.fda.gov/biologicsbloodvaccines/
    safetyavailability/vaccinesafety/ucm096228.htm
    . Accessed August 10, 2018. (Government website)
  101. Chang CG, Jaynes C, Fernandez MC, et al. Pit viper envenomation in pregnancy: a case report and literature review. J Emerg Med. 2006;30(2):167-169. (Case report)
  102. Kravitz J, Gerardo CJ. Copperhead snakebite treated with Crotalidae polyvalent immune fab (ovine) antivenom in third trimester pregnancy. Clin Toxicol (Phila). 2006;44(3):353-354. (Letter to editor)
  103. Sasaki J, Khalil PA, Chegondi M, et al. Coral snake bites and envenomation in children: a case series. Pediatr Emerg Care. 2014;30(4):262-265. (Case series; 4 patients)
  104. Johnson PN, McGoodwin L, Banner W, Jr. Utilisation of Crotalidae polyvalent immune fab (ovine) for Viperidae envenomations in children. Emerg Med J. 2008;25(12):793-798. (Review)
  105. Cribari C. Management of poisonous snakebites. Available at: https://www.facs.org/~/media/files/quality%20programs/
    trauma/publications/snakebite.ashx
    . Accessed August 10, 2018. (Guidelines)
  106. Darracq MA, Cantrell FL, Klauk B, et al. A chance to cut is not always a chance to cure- fasciotomy in the treatment of rattlesnake envenomation: a retrospective poison center study. Toxicon. 2015;101:23-26. (Retrospective; 105 patients)
  107. Tanen DA, Danish DC, Grice GA, et al. Fasciotomy worsens the amount of myonecrosis in a porcine model of crotaline envenomation. Annals of Emergency Medicine. 2004;44(2):99-104. (Animal model)
  108. Better OS, Zinman C, Reis DN, et al. Hypertonic mannitol ameliorates intracompartmental tamponade in model compartment syndrome in the dog. Nephron. 1991;58(3):344-346. (Animal model)
  109. Buchbinder D, Karmody AM, Leather RP, et al. Hypertonic mannitol: its use in the prevention of revascularization syndrome after acute arterial ischemia. Arch Surg. 1981;116(4):414-421. (Animal model)
  110. Ricci MA, Corbisiero RM, Mohamed F, et al. Replication of the compartment syndrome in a canine model: experimental evaluation of treatment. J Invest Surg. 1990;3(2):129-140. (Animal model)
  111. Oredsson S, Plate G, Qvarfordt P. The effect of mannitol on reperfusion injury and postischaemic compartment pressure in skeletal muscle. Eur J Vasc Surg. 1994;8(3):326-331. (Animal model)
  112. Gold BS, Barish RA, Dart RC, et al. Resolution of compartment syndrome after rattlesnake envenomation utilizing non-invasive measures. J Emerg Med. 2003;24(3):285-288. (Case report)
  113. Larson KW, Schaefer KR, Austin C, et al. Management of tissue loss after Agkistrodon snakebite: appropriate use of Crotalidae-Fab antivenin. J Trauma Nurs. 2016;23(3):169-172. (Retrospective; 57 patients)
  114. Lasoff DR, Ruha AM, Curry SC, et al. A new F(ab’)2 antivenom for the treatment of crotaline envenomation in children. Am J Emerg Med. 2016;34(10):2003-2006. (Case series; 21 patients)
  115. United States Food and Drug Administration. Highlights of prescribing information, Anavip. Available at: www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/Approved
    Products/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM446175.pdf
    . Accessed August 10, 2018. (FDA package insert)
  116. Boyer LV, Chase PB, Degan JA, et al. Subacute coagulopathy in a randomized, comparative trial of Fab and F(ab‘)2 antivenoms. Toxicon. 2013;74:101-108. (Randomized trial; 12 patients)
  117. Bush SP, Seifert SA, Oakes J, et al. Continuous IV Crotalidae polyvalent immune Fab (ovine) (FabAV) for selected North American rattlesnake bite patients. Toxicon. 2013;69:29-37. (Retrospective; 5 patients)
  118. Hwang CW, Flach FE. Recurrent coagulopathy after rattlesnake bite requiring continuous intravenous dosing of antivenom. Case Rep Emerg Med. 2015;2015:719302. (Case report)
  119. Nielsen VG, Redford DT, Boyle PK. Effect of iron and carbon monoxide on fibrinogenase-like degradation of plasmatic coagulation by venoms of six Agkistrodon species. Basic Clin Pharmacol Toxicol. 2016;118(5):390-395. (Laboratory testing)
  120. Ruha AM, Curry SC, Albrecht C, et al. Late hematologic toxicity following treatment of rattlesnake envenomation with Crotalidae polyvalent immune Fab antivenom. Toxicon. 2011;57(1):53-59. (Retrospective; 66 patients)
  CME Information

Accreditation: EB Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME.

Credit Designation: EB Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Specialty CME: Included as part of the 4 credits, this CME activity is eligible for 4 Trauma CME credits.

Faculty Disclosures: It is the policy of EB Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. In compliance with all ACCME Essentials, Standards, and Guidelines, all faculty for this CME activity were asked to complete a full disclosure statement.The information received is as follows: Dr. Sheikh, Dr. Leffers, Dr. Sessions, Dr. Mishler, Dr. Toscano, and their related parties report no significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) discussed in this educational presentation. Dr. Jagoda made the following disclosures: Consultant, Daiichi Sankyo Inc; Consultant, Pfizer Inc; Consultant, Banyan Biomarkers Inc; Consulting fees, EB Medicine.

Commercial Support: This issue of Emergency Medicine Practice did not receive any commercial support.

  Related Links

To view this issue, please choose one of the options below:

Purchase a
subscription
$349
Emergency Medicine Practice
 
Purchase issue and
CME test (4 credits)
$39
Emergency Medicine Practice
single issue
Sign up for a free trial
Free 48-hour trial
Emergency Medicine Practice
 

2018 LLSA Prep Study Guides, 35 CME Credits

 
About EB Medicine:
Products:
Accredited By:
ACCME ACCME
AMA AMA
ACEP ACEP
AAFP AAFP
AOA AOA
AAP AAP
Endorsed By:
AEMAA AEMAA
HONcode HONcode
STM STM

 

Last Modified: 11/16/2018
© EB Medicine